ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Valacyclovir: An overview

Valacyclovir: An overview
Literature review current through: Jan 2024.
This topic last updated: Mar 28, 2022.

INTRODUCTION — Valacyclovir is the valyl ester of the antiviral drug acyclovir [1]. Acting as an oral prodrug, valacyclovir is converted in vivo to acyclovir. Acyclovir, a nucleoside analog, is phosphorylated by virally-encoded thymidine kinase and subsequently by cellular enzymes, yielding acyclovir triphosphate, which competitively inhibits viral DNA polymerase. (See "Acyclovir: An overview".)

BASIC PHARMACOKINETICS — The antiviral activity of valacyclovir reflects its in vivo conversion to acyclovir, which is active against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at the oral doses approved by the US Food and Drug Administration [2,3].

Valacyclovir has three to fivefold greater oral bioavailability (about 55 percent) than acyclovir; it then undergoes rapid and extensive first-pass intestinal and/or hepatic hydrolysis to yield acyclovir and L-valine [2,3]. Food does not affect absorption.

Valacyclovir, at a dose of 250 mg four times daily, generates essentially the same acyclovir AUC (area under the curve, or exposure over 24 hours) as oral acyclovir at a dose 800 mg five times daily [3]. Valacyclovir, at a dose of 1000 mg three times daily, produces a similar acyclovir AUC as intravenous acyclovir at a dose of 5 mg/kg every eight hours [4].

Intravenous acyclovir generates higher peak levels than oral valacyclovir. Although this feature may confer more potent activity, it may also increase the risk of renal toxicity due to precipitation of acyclovir crystals in the renal tubules [3] (see "Crystal-induced acute kidney injury"). In addition, the safety of valacyclovir at doses higher than those approved by the US Food and Drug Administration, especially in immunocompromised persons, remains controversial.

The main route of valacyclovir elimination is renal, and dose modification is recommended for patients with a creatinine clearance below 30 mL/min/1.73 m2. Dose adjustment is not required in patients with hepatic impairment [3].

MECHANISM OF RESISTANCE — The mechanisms of resistance to valacyclovir are identical to those described for acyclovir. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host [5]:

Reduced or absent thymidine kinase

Altered thymidine kinase activity resulting in decreased acyclovir phosphorylation

Altered viral DNA polymerase with decreased affinity for acyclovir triphosphate

(See "Acyclovir: An overview", section on 'Mechanism of resistance'.)

TOXICITY — When administered at approved doses (up to 1000 mg three times daily, or two 2000 mg doses separated by 12 hours), valacyclovir has been remarkably well tolerated, similar to the experience with acyclovir [1,3]. (See "Treatment of herpes zoster" and "Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults".)

However, a trial examining the effectiveness of high-dose valacyclovir (2000 mg four times daily) in preventing cytomegalovirus (CMV) disease was halted when interim analysis revealed significantly shorter survival in patients receiving this regimen, with cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome being reported [6]. This complication has also been observed at this high dose in recipients of allogeneic bone marrow or kidney transplants [1].

Much of this phenomenon was attributed to the development of a thrombotic microangiopathy associated with valacyclovir; however, causality has not been established conclusively, since several other medications (fluconazole, ethambutol, clofazimine, trimethoprim-sulfamethoxazole) were also significantly associated with this complication [7]. (See "Drug-induced thrombotic microangiopathy (DITMA)".)

USE IN PREGNANCY — There does not appear to be an increased risk of birth defects when valacyclovir is administered during the first trimester of pregnancy; however, controlled studies documenting safety are lacking. Prospective epidemiologic registries of acyclovir and valacyclovir in pregnancy, which collected data through 1999, found that the rate of birth defects among 784 infants and fetuses exposed to these agents during the first trimester was not significantly different from that of the population not exposed to these agents [1]. Similar findings were demonstrated in a study of 1804 first-trimester pregnancies in Denmark exposed to acyclovir, valacyclovir, or famciclovir from 1996 to 2008, in which the frequency of major birth defects in exposed infants was not increased compared with those who were not exposed (2.2 versus 2.4 percent, adjusted prevalence odds ratio 0.89; 95% CI 0.65-1.22) [8]. With regards to the individual antiviral agents, a major birth defect was diagnosed in 32 of 1561 infants (2.0 percent) with first-trimester exposure to acyclovir and 7 of 229 infants (3.1 percent) with first-trimester exposure to valacyclovir; famciclovir exposure was uncommon, with 1 of 26 infants (3.8 percent) diagnosed with a birth defect.

Although the relatively small size of available data yield insufficient power to draw definitive conclusions regarding the safety of acyclovir and valacyclovir in pregnancy, there are circumstances in which the potential benefits of acyclovir and valacyclovir in pregnancy outweigh the risks, given the high potential morbidity of perinatally acquired herpes simplex virus infection. However, valacyclovir is typically considered an alternative to acyclovir in pregnancy since there is less experience with the use of this agent. (See "Genital herpes simplex virus infection and pregnancy".)

CLINICAL USE — Valacyclovir can generally be regarded as an acceptable alternative to oral acyclovir when this drug is indicated and features a more convenient dosing schedule. The use of valacyclovir in such conditions is discussed elsewhere. (See "B virus infection" and "Treatment of herpes zoster" and "Treatment of genital herpes simplex virus infection" and "Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults".)

SUMMARY AND RECOMMENDATIONS

Valacyclovir is converted in vivo to acyclovir, a nucleoside analog that competitively inhibits viral DNA polymerase. (See 'Introduction' above.)

Valacyclovir is active in vitro against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus (EBV), but is not usually used clinically for EBV infections. Valacyclovir has three to fivefold greater oral bioavailability (about 55 percent) than acyclovir. (See 'Basic pharmacokinetics' above.)

The mechanism of resistance to valacyclovir is identical to that described for acyclovir. Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host: reduced or absent thymidine kinase, altered thymidine kinase activity, and altered viral DNA polymerase with decreased affinity for acyclovir triphosphate. (See 'Mechanism of resistance' above.)

When administered at approved doses (up to 1000 mg three times daily or two 2000 mg doses separated by 12 hours), valacyclovir is well tolerated. (See 'Toxicity' above.)

There does not appear to be an increased risk of birth defects when valacyclovir is administered during the first trimester of pregnancy; however, controlled studies documenting safety are lacking. (See 'Use in pregnancy' above.)

Valacyclovir can generally be regarded as an acceptable alternative to oral acyclovir when this drug is indicated and offers a more convenient dosing schedule. (See 'Clinical use' above.)

Topic 8337 Version 15.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟